PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:50-1:100 |
| Pretreatment | EDTA Buffer pH 8.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Vimentin Information for Pathologists
Summary:
Intermediate filament for mesenchymal tissue. Uses by pathologists Vimentin staining confirms mesenchymal origin of some tumors; may be the only positive stain and thus confirms that the tissue is capable of staining (Am J Surg Pathol 2011;35:1722). Staining may confirm mesenchymal origin, but numerous exceptions so relatively nonspecific. Help distinguish renal cell clear cell carcinoma from mimics as part of panel.
Common Uses By Pathologists:
Vimentin staining confirms mesenchymal origin of some tumors; may be the only positive stain and thus confirms that the tissue is capable of staining (Am J Surg Pathol 2011;35:1722). Staining may confirm mesenchymal origin, but numerous exceptions so relatively nonspecific. Help distinguish renal cell clear cell carcinoma from mimics as part of panel. Absence of vimentin staining may confirm that fat-like or other spaces actually lack a cellular lining (Am J Surg Pathol 2011;35:1823). Distinguish endocervical and endometrial adenocarcinoma, as part of panel (Am J Surg Pathol 2010;34:915).
| Vimentin General Information | |
|---|---|
| Alternate Names | |
| Molecular Weight | |
| 53.7 kDa | |
| Chromosomal Location | |
| p13 [chr: 10] [chr_start: 17228241] [chr_end: 17237593] [strand: 1] | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | VIM |
| Entrez Gene ID | 7431 |
| RefSeq Protein Accession(s) | XP_006717563; NP_003371 |
| RefSeq mRNA Accession(s) | ; XM_006717500; NM_003380 |
| RefSeq Genomic Accession(s) | NC_000010; NG_012413 |
| UniProt ID(s) | P08670 |
| PharmGKB ID(s) | PA37311 |
| KEGG Gene ID(s) | hsa:7431 |
| Associated Diseases (KEGG IDs) | Cataract 30, multiple types (CTRCT30) [MIM:116300]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. In general, the more posteriorly located and dense an opacity, the greater the impact on visual function. {ECO:0000269|PubMed:19126778, ECO:0000269|PubMed:26694549, ECO:0000269|PubMed:28450710}. The disease is caused by mutations affecting the gene represented in this entry. |
| General Description of Vimentin . | |
| This antibody recognizes vimentin. Vimentin is the main intermediate filament protein in mesenchymal cells and is therefore of value in the differential diagnosis of undifferentiated neoplasms. | |
There are no reviews yet.